New risk group staging according to new R-IPSS of 25 patients with low-risk MDS

被引：0
|
作者：
Tatic, A. [1 ]
Jardan, C. [1 ]
Georgescu, O. [1 ]
Stanca, O. [2 ]
Vasilica, M. [1 ]
Badelita, S. [1 ]
Crisan, A. M. [1 ]
Colita, A. [1 ]
Colita, D. [1 ]
Vulcan, G. [3 ]
Lupu, A. R. [2 ]
Coriu, D. [1 ]
机构：
[1] Fundeni Clin Inst, Prof Dr Stefan Berceanu Dept, Hematol & Bone Marrow Transplant, Bucharest, Romania
[2] Coltea Hosp, Dept Hematol, Bucharest, Romania
[3] Hiperdia, Brasov, Romania
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70215-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-167
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [31] Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.
    Follo, Matilda Y.
    Mongiorgi, Sara
    Clissa, Cristina
    Chiarini, Francesca
    Paolini, Stefania
    Baccarani, Michele
    Martinelli, Giovanni
    Manzoli, Lucia
    Martelli, Alberto M.
    Finelli, Carlo
    Cocco, Lucio
    BLOOD, 2009, 114 (22) : 941 - 942
  • [32] A phase-III trial in patients with low-risk MDS (IPSS below 1.5) of long-term-amifostine vs. supportive care.
    Haase, D
    Gassmann, W
    Vehmeyer, K
    Steffens, R
    Stitz, E
    Schanz, J
    Binder, C
    Griesinger, F
    Ludwig, WD
    Wuchter, C
    Kliche, KO
    Hahnfeld, S
    Truemper, L
    Woermann, BJ
    BLOOD, 2001, 98 (11) : 271B - 272B
  • [33] A LONGITUDINAL OBSERVATIONAL STUDY ON THE HEALTH-RELATED QUALITY OF LIFE IN IPSS LOW-RISK MDS - IMPACT OF TIME COURSE AND TRANSFUSION NEED
    Stauder, R.
    Johnston, T.
    Smith, A.
    Droste, J.
    Fenaux, P.
    Symeonidis, A.
    Hellstrom-Lindberg, E.
    Sanz, G.
    Cermak, J.
    Georgescu, O.
    Germing, U.
    MacKenzie, M.
    Beyne-Rauzy, O.
    Malcovati, L.
    Guerci, A.
    Sanhes, L.
    Slama, B.
    Luno, E.
    Bowen, D.
    de Witte, T.
    HAEMATOLOGICA, 2013, 98 : 81 - 81
  • [34] Amifostin long-term application vs. supportive care -: A multicentric phase III trial in patients with low-risk MDS (IPSS < 1.5).
    Haase, D
    Schanz, J
    Gassmann, W
    Yilmaz, A
    Vehmeyer, K
    Ludwig, WD
    Wuchter, C
    Soeling, U
    Pies, A
    Schulz, T
    Verbeek, W
    Bartels, H
    Binder, C
    Griesinger, F
    Cliche, KO
    Woermann, B
    BLOOD, 2000, 96 (11) : 261B - 261B
  • [35] A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS
    Siyu Gu
    Jingya Xia
    Yulu Tian
    Jie Zi
    Zheng Ge
    BMC Cancer, 21
  • [36] A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS
    Gu, Siyu
    Xia, Jingya
    Tian, Yulu
    Zi, Jie
    Ge, Zheng
    BMC CANCER, 2021, 21 (01)
  • [37] From Low-Risk to a New Different Type of High-Risk Transcatheter Aortic Valve Replacement Patients?
    Barbieri, Lucia
    Carugo, Stefano
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 230 : 86 - 87
  • [38] Female patients with "low-risk" mamma carcinoma and HER2-new status
    Stranzl-Lawatsch, H.
    Regitnig, P.
    Peintinger, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 : 65 - 65
  • [39] 5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS
    Fili, C.
    Gobbi, M.
    Martinelli, G.
    Finelli, C.
    Iacobucci, I.
    Ottaviani, E.
    Cocco, L.
    Follo, M.
    Candoni, A.
    Simeone, E.
    Damiani, D.
    Tiribelli, M.
    Miglino, M.
    Lauria, F.
    Bocchia, M.
    Defina, M.
    Clissa, C.
    Skert, C.
    Bergonzi, C.
    Malagola, M.
    Peli, A.
    Turra, A.
    Cattina, F.
    Colombi, C.
    Russo, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 556 - 556
  • [40] Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis
    Sekeres, M.
    Swern, A.
    Fenaux, P.
    Greenberg, P.
    Sanz, G.
    Bennett, J.
    Dreyfus, F.
    Cazzola, M.
    List, A.
    Garcia-Manero, G.
    Li, J. Shiansong
    Sugrue, M.
    LEUKEMIA RESEARCH, 2013, 37 : S69 - S70
12345